CVS, Walgreen Suspend OTC Ranitidine Sales As FDA Investigates Contamination
Executive Summary
CVS, Walgreen suspend sales of brand and store brand ranitidine OTCs while Sanofi confirms it is not recalling Zantac in the US and has no plans to cease manufacturing or distributing.
You may also be interested in...
First Recalls, Now Investors' Concerns Over Ranitidine Litigation Take Pharmas For Wild Ride
Host of complaints in US courts, seeking damages or alleging ranitidine caused various cancers, followed FDA’s 2020 findings of NDMA levels exceeding allowable limits in some samples provoked Litigation is starting to come to trial, the first set for 22 August in Illinois and a bellwether case due to begin in California in February 2023.
OTC Heartburn Remedy Options Remain Robust Without Ranitidine
FDA advising consumers to choose other heartburn OTCs but isn't ordering ranitidine off market. Consumers concerned about Johnson's Baby Powder due to potential asbestos can choose not only from other brands, but also from Johnson's in containers other than 22-ounce option on recall.
OTC Zantac Recall: Sanofi Heeds To Potential Ranitidine Contaminant
Firm opts for recall "as a precautionary measure due to inconsistencies in preliminary test results of the active ingredient used in the US and Canadian products." Other firms marketing ranitidine in US have started recalls due to concerns about NDMA since potential problem became known in September.